EUVIMEDEUVIMED entdecken
CrossrefInfokarte

PRaG regimens for rechallenge in a patient with acquired resistance to PD-1 inhibitor in advanced refractory renal pelvis carcinoma: A case report

Zhihui Hong, Hong Xu, Yuehong Kong, Meiling Xu, Yifu Ma, Pengfei Xing, Liyuan Zhang

Advances in Radiotherapy & Nuclear Medicine · 2023

DOI: 10.36922/arnm.0441 ↗
AbstractBibliografische Angaben

Abstract

Despite the burgeoning popularity of programmed death-1 (PD-1) inhibitors in cancer treatment, it is not uncommon for patients who initially respond to this therapy to experience relapse over time. Here, we present the case of a patient with advanced renal pelvis carcinoma who had received prior treatment with chemotherapy and PD-1 inhibitor therapy but ultimately experienced disease progression. Subsequently, the patient underwent a combination therapy known as PRaG 2.0, which included PD-1 inhibitor, radiotherapy, granulocyte-macrophage colony-stimulating factor, and interleukin-2, resulting in effective disease control without significant adverse events. The duration of disease control lasted for a period of 10 months.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →